Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are able to provide written informed consent~* Patients must have CML in CP which is defined by the presence of all of the following criteria:~  * \< 15% blasts in peripheral blood (PB) and BM.~ * \< 30% blasts plus promyelocytes in PB and BM.~ * \< 20% basophils in the PB.~ * ≥ 100 x 109/L platelets.~ * No evidence of extramedullary leukemia apart from hepatosplenomegaly~ * Ph+ or variants must be demonstrated by BM cytogenetics, FISH or PCR.~ * Previously untreated CML in CP, with the exception of hydroxyurea or anagrelide~* Patients must be enrolled in this study within 90 days after the date of first being diagnosed with CML~* ECOG Performance Status (PS) Score 0 - 1 (see Appendix 2)~* Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional upper limit of normal (ULN) in absence of Gilbert type unconjugated hyperbilirubinemia; alanine aminotransferase (ALAT≤ 2.5 times the institutional ULN.~* Adequate renal function defined as serum creatinine ≤ 2 times the institutional ULN.~* Men and women, ages 18 years and older.~* Adequate BM aspiration sample before the start of study treatment (i.e sample is sufficient for stem cell analysis)~* Potentially fertile women must use an adequate method of contraception to avoid pregnancy throughout the study.~* Potentially fertile women must have a negative serum or urine pregnancy test~Exclusion Criteria:~* Fertile women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study~* Women who are pregnant or breastfeeding.~* Men with fertile sexual partners who can or will not use an acceptable contraception method for the entire study~* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.~* Known pleural effusion at baseline.~* Uncontrolled or significant cardiovascular disease~* History of significant bleeding disorder unrelated to CML, including:~* Prior chemotherapy for peripheral stem cell mobilization.~* Inadequate BM aspiration sample due to marrow fibrosis or other reasons~* Prior or concurrent malignancy~* Severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent~* Abuse of alcohol, prescribed or illicit drugs~* Evidence of digestive dysfunction that would prevent administration of study therapy by mouth.~* Prohibited Treatments and/or Therapies~  * Any prior treatment with interferon~ * Any prior treatment with dasatinib~ * Any prior treatment with imatinib~ * Any other prior systemic treatments, with anti-CML activity \[except for anagrelide, or hydroxyurea (HU)\].~* Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes as described in Appendix 3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: ACTIVE_COMPARATOR): Standard treatment Imatinib 400mg OD
- dasatinib (Type: EXPERIMENTAL): Dasatinib 100mg OD

Based on this trial design, predict the completion outcome and termination type (if applicable).